Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

John J.V. McMurray et al. · PI Novartis Pharmaceuticals

Primary endpoint

Number of Participants That Had First Occurrence of the Composite Endpoint, Which is Defined as Either Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization

Population

Heart Failure With Reduced Ejection Fraction; n=8442

doi:10.1056/NEJMoa1409077

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The PARADIGM-HF trial's stated primary conclusion — Sacubitril/valsartan (ARNI) reduces CV death and HF hospitalization vs. enalapril in HFrEF. — replicates in independent cohorts.

cardiology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of PARADIGM-HF are confirming the original effect size in real-world data.

cardiology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, ARNI will remain preferred over ACEi as baseline RAS modulation in HFrEF across US and EU guidelines.

cardiology

71%